Enest Group Bhd is looking beyond its upcoming transfer to Bursa Malaysia’s ACE Market, using the listing as a launchpad to transform itself from a traditional edible bird’s nest processor into a vertically integrated wellness products player with multiple growth engines aimed at boosting margins and diversifying earnings.
In an exclusive interview with BusinessToday, Managing Director David Tan said the ACE Market transfer represents a strategic inflection point for the group, enabling it to strengthen its balance sheet, expand its value-added product portfolio and deepen its foothold in China, the world’s largest edible bird’s nest market.
Rather than relying solely on its core processing business, Tan highlighted that Enest is laying the groundwork to capture a larger share of the value chain through in-house manufacturing, new customer segments and complementary trading activities.
Moving up the value chain
He shared that at the heart of Enest’s next phase of growth is its planned manufacturing facility in Kajang, which will allow the group to produce its own bottled bird’s nest and herbal beverages instead of outsourcing production.
Tan said bringing manufacturing in-house will give Enest greater control over product quality, shorten product development cycles and provide the flexibility to respond more quickly to evolving consumer preferences.
While processed edible bird’s nest will remain the group’s largest revenue contributor, he said expanding into value-added wellness products marks a natural evolution of the business and is expected to support stronger long-term profitability.
“Our focus will be on strengthening our core bird’s nest processing business while expanding into higher value-added products and new revenue streams,” Tan shared.
Beyond consumer products, Tan highlighted that Enest is also widening its earnings base by targeting traditional Chinese medicine (TCM) manufacturers and expanding its trading of raw unclean bird’s nest into China.
According to Tan, the trading business offers operational advantages through shorter processing lead times, lower operating costs and faster cash conversion, while supplying TCM manufacturers broadens the group’s customer base within China’s growing health and wellness sector.
Although these businesses are still in their early stages, Tan expects them to become increasingly meaningful contributors as the group’s expansion plans gather pace.
Signalling early traction, he said Enest has already secured orders from two contract manufacturers of TCM products in China as at May 26, 2026.
Doubling down on China
Tan emphasised that China remains the centrepiece of Enest’s long-term growth strategy, with the group aiming to leverage its established customer relationships and reputation to capture additional demand.
“Besides increasing exports of raw cleaned edible bird’s nest, the group intends to expand shipments of raw unclean bird’s nest while growing its presence among TCM manufacturers.
“Our competitive advantage lies in its strong supply chain, rigorous quality assurance systems and proven export capabilities,” Tan said, while sharing that its subsidiaries, Ming Feng Marketing (M) Sdn Bhd and Dynamic Transforms Sdn Bhd, are ranked among Malaysia’s top 10 exporters of raw cleaned edible bird’s nest to China by volume, according to the 2025 Bird’s Nest Traceability Report by CAIQ.
“These strengths provide us with a solid foundation to further strengthen our presence in the China market,” he said.
Execution takes centre stage post-IPO
Meanwhile, rather than simply funding expansion, Tan said the IPO proceeds have been allocated to improve Enest’s financial flexibility and execution capabilities.
“We plan to use RM5 million to repay bank borrowings, generating annual interest savings of approximately RM340,000, while RM6.4 million will be channelled into working capital to secure raw unclean bird’s nest during favourable pricing periods,” he noted.
The stronger balance sheet, he said, will enable Enest to maintain a more consistent supply of raw materials, support higher processing volumes and expand both its Malaysian operations and China export business.
Looking ahead, Tan said investors should monitor the progress of the group’s Kajang manufacturing facility, with acquisition targeted in the fourth quarter of 2026 (4Q26) and construction expected to be completed by 3Q27.
“The facility will consolidate Enest’s existing processing operations while underpinning its move into in-house production of bottled bird’s nest and herbal beverages,” he added, while highlighting that other operational milestones will also include expanding the customer base in China, scaling its raw unclean bird’s nest trading business and increasing sales to TCM manufacturers.
In an overview, Tan said the ACE Market transfer ultimately marks the beginning of Enest’s next chapter — not merely as a processor of edible bird’s nest, but as a diversified wellness group seeking to create more sustainable, higher-quality earnings.
“These initiatives will strengthen our core processing business while broadening our revenue streams, supporting sustainable growth and creating long-term shareholder value,” he said.
